DOSING & ADMINISTRATION
MONOFERRIC IS FDA APPROVED
AS A SINGLE, RAPID INFUSION
*Repeat dose if iron deficiency anemia reoccurs.
FOR PATIENTS WEIGHING 50 kg OR MORE: Administer 1000 mg of Monoferric by intravenous infusion ≥20 minutes as a single dose1
FOR PATIENTS WEIGHING LESS THAN 50 kg: Administer Monoferric as 20 mg/kg actual body weight by intravenous infusion ≥20 minutes as a single dose1
Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions
Repeat Monoferric treatment if iron deficiency anemia reoccurs1
Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion1
KEY INSIGHTS FROM REGISTERED NURSE CARRIE SMITH
Carrie Smith, RN, explains why 1 dose is important to her patients.
I was the first nurse to administer Monoferric in the United States after it was commercially available in 2020. I’ve administered various iron preparations, but this one is unique.
You can administer just 1, 1000-milligram dose of Monoferric typically in at least 20 minutes.
I was initially not familiar with a single high dose, but Monoferric was well tolerated by our patients. It was a positive experience for me, just the way that it's administered.
1 dose is important to my patients. When speaking with them, they found the one dose to be convenient and were able to easily fit it into their normal activities.
HAVE A QUESTION ABOUT ADMINISTERING MONOFERRIC?
Sign up to contact a representative and receive information about Monoferric.
LET US HELP
Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:
- who have intolerance to oral iron or have had unsatisfactory response to oral iron
- who have non-hemodialysis dependent chronic kidney disease (NDD-CKD)
IMPORTANT SAFETY INFORMATION
Monoferric is contraindicated in patients with a history of serious hypersensitivity to Monoferric or any of its components. Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.
WARNINGS AND PRECAUTIONS
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Monoferric. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Monoferric is contraindicated in patients with prior serious hypersensitivity reactions to Monoferric or any of its components. In clinical trials in patients with IDA and CKD, serious or severe hypersensitivity were reported in 0.3% (6/2008) of the Monoferric treated subjects. These included 3 events of hypersensitivity in 3 patients; 2 events of infusion-related reactions in 2 patients and 1 event of asthma in one patient.
Excessive therapy with parenteral iron can lead to excess iron storage and possibly iatrogenic hemosiderosis or hemochromatosis. Monitor the hematologic response (hemoglobin and hematocrit) and iron parameters (serum ferritin and transferrin saturation) during parenteral iron therapy. Do not administer Monoferric to patients with iron overload.
Adverse reactions were reported in 8.6% (172/2008) of patients treated with Monoferric. Adverse reactions related to treatment and reported by ≥1% of the treated patients were nausea (1.2%) and rash (1%). Adjudicated serious or severe hypersensitivity reactions were reported in 6/2008 (0.3%) patients in the Monoferric group. Hypophosphatemia (serum phosphate <2.0 mg/dL) was reported in 3.5% of Monoferric-treated patients in Trials 1 & 2.
- Monoferric (ferric derisomaltose) Prescribing Information; Pharmacosmos Therapeutics Inc., Morristown, NJ: 2022.